T1	Participants 79 121	men receiving therapy for prostate cancer.
T2	Participants 611 672	men receiving androgen deprivation for their prostate cancer.
T3	Participants 1166 1292	Multi-site randomized controlled trial of 195 men (65 subjects per arm) undergoing treatment for prostate cancer involving ADT
T4	Participants 1897 1945	androgen deprivation in prostate cancer patients
